Cinclus Pharma (CINPHA.ST) stock: key figures, P/E, revenue and dividend
Health Care · Sweden · ISIN SE0020388577
Cinclus Pharma financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 4.58 m SEK | 57.47 m SEK |
| Operating income | -168.93 m SEK | -198.18 m SEK |
| EBIT | -158.56 m SEK | -183.32 m SEK |
| Net income | -168.03 m SEK | -183.97 m SEK |
| Diluted EPS – continuing operations | -3.61 SEK | -3.95 SEK |
Full history since 2022, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Cinclus Pharma
Cinclus Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops small molecules for the treatment of gastric acid-related diseases in China. The company's lead product is linaprazan glurate, a potassium-competitive acid blocker that has completed Phase II clinical trial to treat gastroesophageal reflux disease. It also develops linaprazan glurate with antibiotics, which is in pre-clinical trial for the treatment of peptic ulcer bacteria Helicobacter pylori. Cinclus Pharma Holding AB (publ) was founded in 2014 and is headquartered in Stockholm, Sweden.
More stocks
- Kns Co., Ltd (432470.KQ)
- Hannan Metals Ltd (HAN.V)
- Professional Computer Technology Ltd (6270.TWO)
- IB Acquisition Corp. (IBAC)
- BASO Precision Optics Co., LTD (6517.TWO)
- Dongsin Engineering & Construction (025950.KQ)
- WORLD HEALTH ENERGY HOLDINGS, INC. (WHEN)
- Aromatica Co. Ltd. (0015N0.KQ)
- Sangsangin Ian No.1 Special Purpose Acquisition Co. Ltd (307870.KQ)
- Hyweb Technology Co Ltd (5212.TWO)
- Tifa Finance Tbk (TIFA.JK)
- Sunborn International Oyj (SBI.HE)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.